Synthesis, Reactivity, and Biological Activity of Gold(I) Complexes Modified with Thiourea-functionalized Tyrosine Kinase Inhibitors

Overview

Journal Inorg Chem

Specialty Chemistry

Date 2015 Mar 21

PMID 25793564

Citations 9

Authors

Mu Yang

Amanda J Pickard

Xin Qiao

Matthew J Gueble

Cynthia S Day

Gregory L Kucera

Ulrich Bierbach

Affiliations

Soon will be listed here.

Abstract

Thiourea-modified 3-chloro-4-fluoroanilino-quinazoline derivatives have been studied as potential receptor-targeted carrier ligands in linear gold(I) complexes. The molecules mimic the epidermal growth factor receptor (EGFR) tyrosine kinase-targeted inhibitor gefitinib. Thiourea groups were either directly attached to quinazoline-C6 (compounds 4, 5, and 7) or linked to this position via a flexible ethylamino chain (compound 9). Compound 7 acts as a thiourea-S/quinazoline-N1 mixed-donor ligand, giving the unexpected dinuclear complex [{Au(μ-7-S,N)}2]X2 (X = Cl(-), SCN(-)) (12a,b) (X-ray crystallography, electrospray mass spectrometry). Derivative 9 forms a stable linear complex, [Au(PEt3)(9-S)](NO3) (13). The biological activity of the carrier ligands and corresponding gold(I) complexes was studied in NCI-H460 and NCI-H1975 lung cancer cells. Compound 9 partially overcomes resistance to gefitinib in NCI-H1975, a lung cancer cell line characterized by a L858R/T790M mutation in EGFR (IC50 values of 1.7 and 30 μM, respectively). The corresponding gold complex (13) maintains activity in the low-micromolar concentration range similar to the metal-free carrier. Compound 9 and the corresponding [Au(PEt3)] complex, 13, inhibit EGFR kinase-mediated phosphorylation with sub-micromolar IC50 values similar to those observed for gefitinib under the same assay conditions. Potential mechanisms of action and reactions in biological media of this new type of hybrid agent, as well as shortcomings of the current design are discussed.

Citing Articles

Homobimetallic Au(I)-Au(I) and Heterotrimetallic Au(I)-Fe(II)-Au(I) Complexes with Dialkyldithiophosphates and Phosphine Ligands: Structural Characterization, DFT Analysis, and Tyrosinase Inhibitory and Biological Effects.

Neshat A, Mahdavi A, Yousefshahi M, Cheraghi M, Mousavizadeh Mobarakeh A, Mohammadi S ACS Omega. 2023; 8(23):20423-20439.

PMID: 37332817 PMC: 10268621. DOI: 10.1021/acsomega.3c00645.

Organometallic gold(I) and gold(III) complexes for lung cancer treatment.

Zhang J, Li Y, Fang R, Wei W, Wang Y, Jin J Front Pharmacol. 2022; 13:979951.

PMID: 36176441 PMC: 9513137. DOI: 10.3389/fphar.2022.979951.

Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity.

Li C, Xu F, Zhao Y, Zheng W, Zeng W, Luo Q Front Chem. 2020; 8:210.

PMID: 32411653 PMC: 7199514. DOI: 10.3389/fchem.2020.00210.

Bioactive Salen-type Schiff Base Transition Metal Complexes as Possible Anticancer Agents.

Damercheli M, Mahdi M, Mehravi B, Shafiee Ardestani M Iran J Pharm Res. 2020; 18(4):2055-2066.

PMID: 32184869 PMC: 7059031. DOI: 10.22037/ijpr.2019.12792.11151.

Platination of cysteine by an epidermal growth factor receptor kinase-targeted hybrid agent.

Yang M, Wu H, Chu J, Gabriel L, Kim Y, Anderson K Chem Commun (Camb). 2018; 54(54):7479-7482.

PMID: 29915817 PMC: 7050444. DOI: 10.1039/c8cc04251a.

References

Zhou W, Ercan D, Chen L, Yun C, Li D, Capelletti M . Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009; 462(7276):1070-4. PMC: 2879581. DOI: 10.1038/nature08622. View

Dempke W, Suto T, Reck M . Targeted therapies for non-small cell lung cancer. Lung Cancer. 2009; 67(3):257-74. DOI: 10.1016/j.lungcan.2009.10.012. View

Eiter L, Hall N, Day C, Saluta G, Kucera G, Bierbach U . Gold(I) analogues of a platinum-acridine antitumor agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis. J Med Chem. 2009; 52(21):6519-22. PMC: 3176588. DOI: 10.1021/jm9012856. View

Gandin V, Fernandes A, Rigobello M, Dani B, Sorrentino F, Tisato F . Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem Pharmacol. 2009; 79(2):90-101. DOI: 10.1016/j.bcp.2009.07.023. View

Marcaurelle L, Comer E, Dandapani S, Duvall J, Gerard B, Kesavan S . An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J Am Chem Soc. 2010; 132(47):16962-76. PMC: 3004530. DOI: 10.1021/ja105119r. View

Akerman K, Fagenson A, Cyril V, Taylor M, Muller M, Akerman M . Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I. J Am Chem Soc. 2014; 136(15):5670-82. PMC: 4004252. DOI: 10.1021/ja412350f. View

Yoshida T, Zhang G, Haura E . Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010; 80(5):613-23. DOI: 10.1016/j.bcp.2010.05.014. View

Hamed M, Abou El Ella D, Keeton A, Piazza G, Abadi A, Hartmann R . 6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines. ChemMedChem. 2013; 8(9):1495-504. DOI: 10.1002/cmdc.201300147. View

Cha M, Lee K, Kim J, Lee C, Song J, Kim Y . Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer. J Med Chem. 2009; 52(21):6880-8. DOI: 10.1021/jm901146p. View

10.

Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage S, Jones L . Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol. 2013; 20(2):146-59. PMC: 3583020. DOI: 10.1016/j.chembiol.2012.12.006. View

11.

Fernandez-Gallardo J, Elie B, Sulzmaier F, Sanau M, Ramos J, Contel M . Organometallic Titanocene-Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties. Organometallics. 2014; 33(22):6669-6681. PMC: 4245150. DOI: 10.1021/om500965k. View

12.

Yan K, Lok C, Bierla K, Che C . Gold(I) complex of N,N'-disubstituted cyclic thiourea with in vitro and in vivo anticancer properties-potent tight-binding inhibition of thioredoxin reductase. Chem Commun (Camb). 2010; 46(41):7691-3. DOI: 10.1039/c0cc01058h. View

13.

Abbehausen C, Peterson E, de Paiva R, Corbi P, Formiga A, Qu Y . Gold(I)-phosphine-N-heterocycles: biological activity and specific (ligand) interactions on the C-terminal HIVNCp7 zinc finger. Inorg Chem. 2013; 52(19):11280-7. DOI: 10.1021/ic401535s. View

14.

Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

15.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

16.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

17.

Zhang J, Yang P, Gray N . Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2008; 9(1):28-39. DOI: 10.1038/nrc2559. View

18.

Gajiwala K, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S . Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure. 2013; 21(2):209-19. DOI: 10.1016/j.str.2012.11.014. View

19.

Deng J, Shimamura T, Perera S, Carlson N, Cai D, Shapiro G . Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 2007; 67(24):11867-75. DOI: 10.1158/0008-5472.CAN-07-1961. View

20.

Ahmad S, Isab A . (13)C, (31)P and (15)N NMR studies of the ligand exchange reactions of auranofin and chloro(triethylphosphine)gold(I) with thiourea. J Inorg Biochem. 2001; 88(1):44-52. DOI: 10.1016/s0162-0134(01)00305-1. View